Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Posch

Showing results (1-10 of 166) with videos related to

Pageof 17
Sort By:
Journal of Biopharmaceutical Statistics|April 26, 2011
Special issue for dealing with multiplicity in drug development: current state and new directions--guest editors' noteAlex Dmitrienko, Martin Posch
BMC Bioinformatics|May 8, 2012
False discovery rate control in two-stage designsSonja Zehetmayer, Martin Posch
Statistics in Biopharmaceutical Research|April 30, 2019
Adaptive Budgets in Clinical TrialsMartin Posch, Peter Bauer
Bioinformatics (Oxford, England)|March 2, 2010
Post hoc power estimation in large-scale multiple testing problemsSonja Zehetmayer, Martin Posch
Statistics in Medicine|June 28, 2012
Unplanned adaptations before breaking the blindMartin Posch, Michael A Proschan
Statistics in Medicine|December 24, 2015
Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labelsMagdalena Żebrowska, Martin Posch, Dominic Magirr
BMC Bioinformatics|September 24, 2022
Impact of adaptive filtering on power and false discovery rate in RNA-seq experimentsSonja Zehetmayer, Martin Posch, Alexandra Graf
Journal of Biopharmaceutical Statistics|April 26, 2011
Familywise error control in multi-armed response-adaptive two-stage designsGeorg Gutjahr, Martin Posch, Werner Brannath
Statistics in Medicine|December 2, 2025
Graph Based, Adaptive, Multiarm, Multiple Endpoint, Two-Stage DesignsCyrus Mehta, Ajoy Mukhopadhyay, Martin Posch
The Lancet. Oncology|January 1, 2022
Assessment of tumour-agnostic therapies in basket trialsOlivier Collignon, Martin Posch, Anja Schiel
Pageof 17

Showing results (1-10 of 166) with videos related to

Sort By:
Pageof 17
Journal of Biopharmaceutical Statistics|April 26, 2011
Special issue for dealing with multiplicity in drug development: current state and new directions--guest editors' noteAlex Dmitrienko, Martin Posch
BMC Bioinformatics|May 8, 2012
False discovery rate control in two-stage designsSonja Zehetmayer, Martin Posch
Statistics in Biopharmaceutical Research|April 30, 2019
Adaptive Budgets in Clinical TrialsMartin Posch, Peter Bauer
Bioinformatics (Oxford, England)|March 2, 2010
Post hoc power estimation in large-scale multiple testing problemsSonja Zehetmayer, Martin Posch
Statistics in Medicine|June 28, 2012
Unplanned adaptations before breaking the blindMartin Posch, Michael A Proschan
Statistics in Medicine|December 24, 2015
Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labelsMagdalena Żebrowska, Martin Posch, Dominic Magirr
BMC Bioinformatics|September 24, 2022
Impact of adaptive filtering on power and false discovery rate in RNA-seq experimentsSonja Zehetmayer, Martin Posch, Alexandra Graf
Journal of Biopharmaceutical Statistics|April 26, 2011
Familywise error control in multi-armed response-adaptive two-stage designsGeorg Gutjahr, Martin Posch, Werner Brannath
Statistics in Medicine|December 2, 2025
Graph Based, Adaptive, Multiarm, Multiple Endpoint, Two-Stage DesignsCyrus Mehta, Ajoy Mukhopadhyay, Martin Posch
The Lancet. Oncology|January 1, 2022
Assessment of tumour-agnostic therapies in basket trialsOlivier Collignon, Martin Posch, Anja Schiel
Pageof 17